Dual-epitope targeting of TSLP to simultaneously block TSLPR and IL-7Rα with a Biparatopic nanobody
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115474 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Han-Lin Shen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Biorheological Science and Technology of Chinese Ministry of Education, National Local Joint Engineering Lab for Vascular Implants…. Hauptthemen laut MEDLINE: Cytokines, Single-Domain Antibodies, Epitopes, Receptors, Interleukin-7. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that plays a crucial role in the pathophysiology of asthma, initiating multiple allergic cascade responses. Tezepelumab is the only monoclonal antibody currently approved for marketing, which acts by blocking TSLP binding to TSLPR. However, it is reported that a TSLP trap which simultaneously block TSLP binding with TSLPR and IL-7Rα has better efficiency in the repression of TSLP signal pathway. In this study, we identified two monovalent nanobodies targeting TSLP through immunization of alpacas and phage display screening. They could block TSLP binding with the TSLPR and IL-7Rα receptors, respectively. Then, various protein linkers were designed between these two monovalent nanobodies to form different biparatopic nanobodies. We found that the affinity and biological activity of biparatopic nanobodies are related to the length of the linkers and the tandem order of the nanobodies. We screened a biparatopic nanobody CRNB909, which exhibits extremely high binding affinity for human TSLP with a KD < 1E-12 M, demonstrating approximately 40-fold greater potency compared to the Tezepelumab antibody (KD = 3.98E-11 M). Furthermore, it shows superior functional activity in biological assays, displaying 9.2-fold enhanced inhibition of TSLP-mediated JAK-STAT signaling pathway activation and 4.3-fold greater suppression of TSLP-induced BAF3 cell proliferation relative to Tezepelumab. Finally, CRNB909 was successfully secretory expressed in Komagataella phaffii with reduced production costs. This study provides a biparatopic nanobody that could bind TSLP to simultaneously block TSLPR and IL-7Rα, which might be a promising therapeutant for TSLP related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Biorheological Science and Technology of Chinese Ministry of Education, National Local Joint Engineering Lab for Vascular Implants, College of Bioengineering, Chongqing University, Chongqing 400044, C…
- China Resources Biopharmaceutical Co., Ltd, Unit 601, Building No. 2, YESUN Intelligent Community III, Guanlan Street, Shenzhen 518100, China.
- China Resources Biopharmaceutical Co., Ltd, Unit 601, Building No. 2, YESUN Intelligent Community III, Guanlan Street, Shenzhen 518100, China. Electronic address: guochunyu10@crpharm.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Shen, H. L., Wang, X. L., Liu, Y. H., Chen, C. J., Yin, C. X., Yang, Y. H., Huang, L. M., Guo, C. Y., & Wang, G. X. (2025). Dual-epitope targeting of TSLP to simultaneously block TSLPR and IL-7Rα with a Biparatopic nanobody. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115474
Vancouver
Shen HL, Wang XL, Liu YH, Chen CJ, Yin CX, Yang YH, et al. Dual-epitope targeting of TSLP to simultaneously block TSLPR and IL-7Rα with a Biparatopic nanobody. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115474
BibTeX
@article{Shen2025,
author = {Shen, Han-Lin and Wang, Xiao-Long and Liu, Yue-Hong and Chen, Cui-Juan and Yin, Cai-Xia and Yang, Yan-Hua and Huang, Li-Mei and Guo, Chun-Yu and Wang, Gui-Xue},
title = {Dual-epitope targeting of TSLP to simultaneously block TSLPR and IL-7Rα with a Biparatopic nanobody},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115474}
}
EUVIMED